

FORM PTO-1449
(REV. 7-99)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.419C7APPLICATION NO.
09/534,825SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

APPLICANTS

Tony N. Frudakis et al.

FILING DATE

March 23, 2000

GROUP ART UNIT

1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
anh	AA	5,912,143	06/15/99	Bandman et al.	435	69.1	
↓	AB	6,225,054	05/01/01	Frudakis et al.	435	6	
↓	AC	6,329,505	12/11/01	Xu et al.	530	350	
↓	AD	6,344,550	02/05/02	Frudakis et al.	536	23.5	
	AE						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
anh	AF	EP 1033401 A2	09/06/00	EPO		
↓	AG	WO 99/06550	02/11/99	WIPO		
↓	AH	WO 99/31236	06/24/99	WIPO		
↓	AI	WO 01/51628	07/19/01	WIPO		
	AJ					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

anh	AK	Ahn and Kunkel, "The structural and functional diversity of dystrophin," <i>Nature Genetics</i> 3:283-291, April 1993.
↓	AL	Attwood, T.K., "The Babel of Bioinformatics," <i>Science</i> 290: 471-473, October 20, 2000.
↓	AM	Boon, T., "Toward a Genetic Analysis of Tumor Rejection Antigens," <i>Adv. Cancer Res.</i> 58:177-210,
↓	AN	Burgess et al., "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," <i>Journal of Cell Biology</i> 111: 2129-2138, November 1990.
↓	AO	Cawthon et al., "cDNA Sequence and Genomic Structure of <i>EVI2B</i> , a Gene Lying with an Intron of the Neurofibromatosis Type 1 gene," <i>Genomics</i> 9: 446-460, 1991.
↓	AP	Curti, B.D., "Physical barriers to drug delivery in tumors," <i>Critical Reviews in Oncology/Hematology</i> 14:29-39, 1993.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-88)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

210121.419C7

APPLICATION NO.

09/534,825

APPLICANTS

Tony N. Frudakis et al.

FILING DATE

March 23, 2000

GROUP ART UNIT

1642

SECOND SUPPLEMENTAL

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
BB					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

amh	BC	Dermer, G.B., "Another Anniversary for the War on Cancer," <i>Bio/Technology</i> 12: 320, March 1994.
	BD	Drexler, H. "Recent Results on the Biology of Hodgkin and Reed-Sternberg cells. II. Continuous Cell Lines," <i>Leukemia and Lymphoma</i> 9: 1-25, 1993.
	BE	Embleton, M.J., "Monoclonal Antibodies to Osteogenic Sarcoma Antigens," in <i>Monoclonal Antibodies and Cancer, Immunology Series 23</i> , Wright, Jr. G.L. (ed.), Marcel Dekker, New York, NY, 1984, pp. 181-207.
	BF	Freshney, R.I., <i>Culture of Animal Cells: A Manual of Basic Technique</i> , Alan R. Liss, Inc., New York, 1983, pp.3-4.
	BG	GenBank Accession No. AA533501, August 1, 1997.
	BH	GenBank Accession No. AC018804, February 11, 2003.
	BI	GenBank Accession No. AI804733, July 6, 1999.
	BJ	GenBank Accession No. AQ063365, July 30, 1998.
	BK	GenBank Accession No. AQ124119, August 31, 1998.
	BL	Geneseq (Derwent) Accession No. AAV68996, January 22, 1999.

EXAMINER

amh

DATE CONSIDERED

May 23, 2003

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

210121.419C7

APPLICATION NO.

09/534,825

APPLICANTS

Tony N. Frudakis et al.

FILING DATE

March 23, 2000

GROUP ART UNIT

1642

SECOND SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
CB					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CC	Genseq (Derwent) Accession No. AAL10921, December 7, 2001.
CD	Genseq (Derwent) Accession No. AAL11383, December 7, 2001.
CE	Genseq (Derwent) Accession No. AAL11455, December 7, 2001.
CF	Genseq (Derwent) Accession No. AAL13620, December 7, 2001.
CG	Genseq (Derwent) Accession No. AAL18685, December 7, 2001.
CH	Genseq (Derwent) Accession No. AAL20282, December 7, 2001.
CI	Genseq (Derwent) Accession No. AAL20354, December 7, 2001.
CJ	Genseq (Derwent) Accession No. AAL22489, December 7, 2001.
CK	Gerhold and Caskey, "It's the genes! EST access to human genome content," <i>BioEssays</i> 18(12): 973-981, 1996.
CL	Geysen et al., "Cognitive Features of Continuous Antigenic Determinants," <i>Journal of Molecular Recognition</i> 1(1): 32-41, 1988.
CM	Gillies and Wesolowski et al., "Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities," <i>Hum. Antibod. Hybridomas</i> 1(1): 47-54, 1990.
CN	Harris et al., "Polycystic Kidney Disease 1: Identification and Analysis of the Primary Defect," <i>Journal of the American Society of Nephrology</i> 6(4): 1125-1133, October 1995.
CO	Hartwell et al., "Integrating Genetic Approaches into the Discovery of Anticancer Drugs," <i>Science</i> 278: 1064-1068, November 7, 1997.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

RECEIVED
FEB 28 2003
TECH CENTER 1600/2900

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

APPLICATION NO.

(REV. 7-80)

210121.419C7

09/534,825

SECOND SUPPLEMENTAL

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Tony N. Frudakis et al.

FILING DATE

March 23, 2000

GROUP ART UNIT

1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING IF APPROPRIATE
DA						

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
DB			


OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DC	Hsu, T.C., "Karyology of Cells in Culture," in Tissue Culture: Methods and Applications, Kurse, Jr et al. (eds.), Academic Press, New York, 1973, pp. 764-767.
DD	Jain, R. K., "Barriers to Drug Delivery in Solid Tumors," <i>Scientific American</i> 271(1): 58-65, July 1994.
DE	Johnstone and Thorpe (eds.), <i>Immunochemistry in Practice</i> , Second Edition, Blackwell Scientific Publications, Oxford England, 1987, pp 49-50.
DF	Lazar et al., "Transforming Growth Factor α : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," <i>Molecular and Cellular Biology</i> 8: 1247-1252, March 1988.
DG	Russell and Barton, "Structural Features can be Unconserved in Proteins with Similar Folds. An Analysis of Side-chain to Side-chain Contacts Secondary Structure and Accessibility," <i>J. Mol. Biol.</i> 244: 332-350, 1994.
DH	Tao and Morrison, "Studies of Aglycosylated Chimeric Mouse-Human IgG. Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region," <i>Journal of Immunity</i> 143(8): 2595-2601, October 15, 1989.
DI	Venter et al., "Genome sequence analysis: scientific objectives and practical strategies," <i>Trends in Biotechnology</i> 10: 8-11, Jan/Feb 1992.
DJ	Walter, G., "Production of use of antibodies against synthetic peptides," <i>Journal of Immunological Methods</i> 88: 149-161, 1986.
DK	Wei et al., "Protection against mammary tumor growth by vaccination with full-length, modified human <i>ErbB-2</i> DNA," <i>Int. J. Cancer</i> 81: 748-754, 1999.
DL	Wells and Peitsch, "The chemokine information source: identification and characterization of novel chemokines using the WorldWideWeb and Expressed Sequence Tag Databases," <i>Journal of Leukocyte Biology</i> 61: 545-550, May 1997.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s)



FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.419C7APPLICATION NO.
09/534,825THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT

(Use several sheets if necessary)

APPLICANTS
Tony N. Frudakis et al.FILING DATE
March 23, 2000GROUP ART UNIT
1642

RECEIVED

APR 01 2003

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
amh	AK	WO 01/25272	04/12/01	WIPO	✓	
	AL					
	AM					
	AN					
	AO					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AP	
AQ	
AR	

EXAMINER

AM Harris

DATE CONSIDERED

23 May 2003

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).